Building A Global Pharmaceutical Traceability Foundation - Presentation Transcript
Building a Global Traceability Foundation to Drive Visibility, Efficiency and Compliance Common Misconceptions and Key Considerations Robin Koh, Chief Strategy Officer, SupplyScape Corporation
Agenda
Main Drivers for Global Track and Trace
Key Considerations for Building Global Traceability Foundation
4 Common Misconceptions
Implementation Approach to Global Serialization
Key Takeaways
Safe & Secure Supply Chain Model Safe and Secure Supply Chain Pharmaceutical Co Wholesaler Pharmacy Chain of Custody Security Transaction Security Trace Track Pedigree Individual Product Security Product Security Product Authentication ID Authentication Authentication
Drivers For Global Traceability Regulatory Compliance Product Security Global Traceability Regulatory Compliance States considering pedigree laws / rules PDMA in effect. No state activity States with pedigree laws / rules today US Pedigree Regulations In place In development Global Serialization & Codification Regulations 70% Medical Professional 18% Subscriber Global Pharma Safety Incidents Sources: Organisation for Economic Co-operation and Development 964 04 196 02 484 03 1,123 05 1,412 06 1,759 07 Product Security Source: BCBSA Survey of Blue Plans’ Anti-Fraud Programs Reimburse In-accuracy 5% Med Unnec. 36% Services Not Rendered 9% Excess Charges 35% Other (1) 2% Pharm Fraud 4% Service Over Utilization 9% Upcoded Service
Complexity of Global Serialization Proliferation of Regulatory Requirements
Time to implement serialization is usually underestimated
Flexibility to handle future requirements is often overlooked
Business benefits are difficult to quantify
Agenda
Main Drivers for Global Track and Trace
Key Considerations for Building Global Traceability Foundation
4 Common Misconceptions
Implementation Approach to Global Serialization
Key Takeaways
Misconception #1: ‘ I Can Wait’
Case Study
A global manufacturer planning for France’s (CIP13) 2D Data Matrix requirement in 2011
Lesson’s Learned
Many variables lengthen the time for implementation
Number of qualified vendors available
Working with CMO networks is more involved than expected
Piloting 1 or 2 packaging lines does not adequately prepare for the scalability issues associated with a corporate roll-out
The Plan is Nothing, but Planning is Everything Dwight D Eisenhower
Misconception #2: ‘Serialization has Limited ROI’ Least Realistic More Realistic CAPEX Packaging CAPEX ACF Program ACF Impact on Line Efficiency Additional Labor Data Monitoring CAPEX-Internal Additional Label Cost CAPEX CMO CAPEX DC Software Maintenance Recurring Benefit CAPEX - One Time Running Cost CAPEX IT Anti-Counterfeit Program #2 Patient Safety Program #1 Label Standardize Program Sales Enhancement Program #2 Anti-Counterfeit Program #1 Recall Enhancement Program Supply Chain Efficiency Program SC Visibility Program #1 Sales Enhancement Program #1 Data Reform Program Benefit Programs by Level of Effort Required and the Magnitude of Benefit Upside Potential Downside Impact
Misconception #3 ‘ Countries are Driving Towards One Standard’
Case Study
In the original design of the MIT solution, there is a fundamental assumption that there will be a homogenous number management system
Lesson’s Learned
Harmonizing on data carriers & numerical structure are different things
Number assignment from multiple sources
Random numbers and non-sequential numbers are different things
There is no guarantee on future requirements
Your Requirements vs. Available Solutions
Misconception # 4 ‘ Serial Number Lookup is an Authentication System’
Building a more complete system :
Alert Patients on Adverse Events in Real Time (e.g. Recall)
Provide Accurate Data for Detection and Prevention in addition to Investigation
Pattern, Pace & Place
Detect False Positives
Authenticate Physical Anti-Counterfeiting Features
Product Security Product Authentication ID Authentication Authentication Individual Product Security
Agenda
Main Drivers for Global Track and Trace
Key Considerations for Building Global Traceability Foundation
4 Common Misconceptions
Implementation Approach to Global Serialization
Key Takeaways
Suggested Approach to Global Serialization Global Framework, Local Alignment
Develop a clear understanding of costs, timing, resources and operational changes needed to meet requirements
Develop local guidance based on corporate standards
Construct and execute a plan to address immediate requirements using localized approach
Build a migration plan to integrate into corporate strategy
Execute the integration plan to migrate local solution into global strategy
Define Global Strategy & Guidelines Address Local Requirements Migrate To Global Plan
Agenda
Main Drivers for Global Track and Trace
Key Considerations for Building Global Traceability Foundation
4 Common Misconceptions
Implementation Approach to Global Serialization
Key Takeaways
Serialization is Global and Uncoordinated
EU, China and USA moving in parallel
Manufacturers must Assume a Global Perspective
There are a set of concrete steps you can take
Serialization can Provide ROI if you know where to look
Few Vendors Understand the Global Issues and Misconceptions
Key Takeaways
Looking Forward Business Opportunities in Supply Chain Traceability
What if you could?
Leverage investments in product serialization initiatives to drive a higher return on product and brand protection?
Increase new product launch success by ensuring proper supply into key markets?
Establish a global network of trading partners to provide greater visibility into distribution channels ?
Overcome barriers to entry into new markets by more efficiently addressing local distribution requirements?
Facilitate financial reconciliation across chargeback, rebate, and re-imbursements across your supply network?
Next Steps Get Started on Developing a Global Traceability Foundation Contact Mary Hall today to schedule a consultation! 781.503.7462, mhall@supplyscape.com Visit SupplyScape.com to learn more www.supplyscape.com
Traceability of pharmaceutical products as they mov more
Traceability of pharmaceutical products as they move through the global supply chain. Regulations, technology standards, trading partner interoperability can all be barriers for companies seeking to gain the benefits of supply chain visibility and collaboration. Join SupplyScape in reviewing the key considerations and common misconceptions about pharmaceutical traceability. less
0 comments
Post a comment